


=> d 11  
L1 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 07:46:41 ON 27 JUL 2004)

FILE 'REGISTRY' ENTERED AT 07:46:54 ON 27 JUL 2004

L1 STRUCTURE UPLOADED  
L2 1 S L1  
L3 50 S L1 FULL  
L4 50 S L3 AND CAPLUS/LC  
L5 0 S L3 AND CAOLD/LC  
L6 0 S L3 AND REF.CAPLUS>10

FILE 'CAPLUS' ENTERED AT 07:52:31 ON 27 JUL 2004

L7 3 S L3


L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2002:483072 CAPLUS  
DOCUMENT NUMBER: 137:47109  
TITLE: Preparation of trisubstituted indole derivatives for inhibiting neoplastic cells  
INVENTOR(S): Pamukcu, Rifat; Piazza, Gary A.  
PATENT ASSIGNEE(S): Cell Pathways, Inc., USA  
SOURCE: U.S., 76 pp., Cont.-in-part of U. S. 6,046,199.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6410584	B1	20020625	US 1998-199860	19981125
US 6046199	A	20000404	US 1998-7098	19980114
US 2002143022	A1	20021003	US 2002-71639	20020207
PRIORITY APPLN. INFO.:			US 1998-7098	A2 19980114
			US 1998-199860	A3 19981125

OTHER SOURCE(S) : MARPAT 137:47109

GI



AB Title compds. I [R1-3 = H, alkyl, alkylthio alkoxy, with the proviso that R1-3 are not simultaneously hydrogen atoms; R4 = H, alkyl; R5 = carboxy, an esterified carboxy group, or an amidated carboxy group] were prepared. For instance, 6-methoxycarbonyl-2-methylindole was N-alkylated with 2-chlorobenzyl bromide (DMF, K<sub>2</sub>CO<sub>3</sub>, 80°C, 18 h); the product saponified and the resulting acid coupled to benzenesulfonamide (DMF, CDI, DBU) to afford II. I are used for inhibiting the growth of neoplastic cells (no data).


IT 206065-16-9P, 5-((Benzenesulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole 206065-31-8P, 3-(2,4-Dichlorobenzyl)-5-[[[(4-methoxybenzene)sulfonyl]carbamoyl]-2-methylindole 206065-53-4P, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(4-methylbenzene)sulfonyl]carbamoyl]indole 206065-55-6P, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(4-nitrobenzene)sulfonyl]carbamoyl]indole 206065-57-8P, 5-[[[(4-Chlorobenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole 206065-59-0P, 5-[[[(3-Chlorobenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole 206065-61-4P, 5-[[[(2-Chlorobenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole 206065-62-5P

y1]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-63-6P**,  
 3-(2,4-Dichlorobenzyl)-5-[[[(4-fluorobenzene)sulfonyl]carbamoyl]-2-methylindole **206065-64-7P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(2-naphthalene)sulfonyl]carbamoyl]indole **206065-65-8P**,  
 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[naphthalen-1-yl)sulfonyl]carbamoyl]indole **206065-66-9P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(2-methylbenzene)sulfonyl]carbamoyl]indole **206065-68-1P**, 5-((4-Bromobenzene)sulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole **206065-70-5P**,  
 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(4-vinylbenzene)sulfonyl]carbamoyl]indole **206065-71-6P**, 5-[[[(4-(Phenylazo)benzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-72-7P**,  
 3-(2,4-Dichlorobenzyl)-2-methylindole **206065-74-9P**, 3-(2,4-Dichlorobenzyl)-5-[[[(3,4-dimethoxybenzene)sulfonyl]carbamoyl]-2-methylindole **206065-76-1P**,  
 , 5-[[[(4-tert-Butylbenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-77-2P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(3-methylbenzene)sulfonyl]carbamoyl]indole **206065-81-8P**,  
 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(4-phenylbenzene)sulfonyl]carbamoyl]indole **206065-83-0P**, 5-((Benzenesulfonyl)carbamoyl)-3-[2-chloro-4-phenylbenzyl]-2-methylindole **206065-85-2P**, 5-[[[(4-n-Butylbenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-86-3P**, 5-[[[(4-(Butoxy)benzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-96-5P**,  
 3-[(1-Bromonaphthalen-2-yl)methyl]-2-methyl-5-[[[(4-vinylbenzene)sulfonyl]carbamoyl]indole **206065-98-7P**,  
 5-[[Benzenesulfonyl]carbamoyl]-3-[(1-bromonaphthalen-2-yl)methyl]-2-methylindole **206066-00-4P**, 3-[2-Chloro-4-phenylbenzyl]-2-methyl-5-[[[(4-vinylbenzene)sulfonyl]carbamoyl]indole **206066-02-6P**,  
 3-[2-Chloro-4-phenylbenzyl]-2-methyl-5-[[4-methylphenylsulfonyl]carbamoyl]indole **438003-21-5P**, 3-(2,4-Dichlorobenzyl)-5-(((2,5-dimethylbenzene)sulfonyl)carbamoyl)-2-methylindole **438003-26-0P**,  
 3-(2,4-Dichlorobenzyl)-5-[[[(4-ethylbenzene)sulfonyl]carbamoyl]-2-methylindole **438003-36-2P**, 3-[(1-Bromonaphthalen-2-yl)methyl]-2-methyl-5-[[p-toluenesulfonyl]carbamoyl]indole  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; preparation of trisubstituted indole derivs. for inhibiting neoplastic cells)


RN 206065-16-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-31-8 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-methoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-53-4 CAPLUS  
 CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 206065-55-6 CAPLUS  
 CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-nitrophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-57-8 CAPLUS  
 CN 1H-Indole-5-carboxamide, N-[(4-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-59-0 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(3-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-61-4 CAPLUS


CN 1H-Indole-5-carboxamide, N-[(2-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-63-6 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-chlorophenyl)sulfonyl]-

fluorophenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-64-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-65-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(1-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-66-9 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-68-1 CAPLUS  
 CN 1H-Indole-5-carboxamide, N-[(4-bromophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-70-5 CAPLUS  
 CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-71-6 CAPLUS  
 CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-phenylazo)phenyl]sulfonyl- (9CI) (CA INDEX NAME)




RN 206065-72-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-(trifluoromethyl)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-74-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(3,4-dimethoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-76-1 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-(1,1-dimethylethyl)phenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-77-2 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(3-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 206065-81-8 CAPLUS


CN 1H-Indole-5-carboxamide, N-([1,1'-biphenyl]-4-ylsulfonyl)-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-83-0 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-


N- (phenylsulfonyl) - (9CI) (CA INDEX NAME)




RN 206065-85-2 CAPLUS  
 CN 1H-Indole-5-carboxamide, N-[(4-butylphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-86-3 CAPLUS  
 CN 1H-Indole-5-carboxamide, N-[(4-butoxyphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-96-5 CAPLUS  
 CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-98-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206066-00-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-[(4-ethenylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206066-02-6 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 438003-21-5 CAPLUS  
 CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(2,5-dimethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 438003-26-0 CAPLUS  
 CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-ethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 438003-36-2 CAPLUS  
 CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-[(2-methoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

methylphenyl)sulfonyl] - (9CI) (CA INDEX NAME)





REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 1998:239201 CAPLUS  
 DOCUMENT NUMBER: 128:294695  
 TITLE: Preparation and formulation of indole derivatives as hypoglycemics and phosphodiesterase 5 inhibitors  
 INVENTOR(S): Yamasaki, Noritsugu; Imoto, Takafumi; Murai, Yoshiyuki; Hiramura, Takahiro; Onomura, Osamu; Nishikawa, Masahiro; Oku, Teruo; Sawada, Kouzou; Kayakiri, Hiroshi; et al.  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 184 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9815530	A1	19980416	WO 1997-JP3592	19971007
W: AU, BR, CA, CN, HU, IL, JP, KR, MX, NZ, RU, SG, TR, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, NL, PT, SE				
AU 9744005	A1	19980505	AU 1997-44005	19971007
ZA 9708998	A	19980420	ZA 1997-8998	19971008
PRIORITY APPLN. INFO.:			JP 1996-287676	A 19961008
			JP 1997-187536	A 19970627
			WO 1997-JP3592	W 19971007

OTHER SOURCE(S): MARPAT 128:294695  
 GI




AB The title compds. I [R1 - R3 = H, alkyl, etc.; a proviso is given; R4 = H,


alkyl; R5 = carboxy, etc.] are prepared I are useful as remedies for impaired glucose tolerance, diabetes, complication of diabetes, insulin resistant syndrome, hyperlipidemia, atherosclerosis, cardiovascular diseases, hyperglycemia, hypertension; diseases characterized by angina pectoris, high blood pressure, pulmonary hypertension, congestive heart failure, glomerular diseases, tubular interstitial diseases, renal insufficiency, atherosclerosis, angiostenosis, peripheral vascular diseases, cerebral stroke, chronic reversible obstructive diseases, allergic rhinitis, urticaria, glaucoma or intestinal motility disorders; sexual impotence, osteoporosis, nephritis, cancerous cachexia or post-PTCA reconnection. The title compound II at 10 mg/kg gave 46% decrease of blood sugar in mice.

IT 206065-16-9P 206065-31-8P 206065-53-4P  
 206065-55-6P 206065-57-8P 206065-59-0P  
 206065-61-4P 206065-63-6P 206065-64-7P  
 206065-65-8P 206065-66-9P 206065-67-0P  
 206065-68-1P 206065-70-5P 206065-71-6P  
 206065-72-7P 206065-74-9P 206065-76-1P  
 206065-77-2P 206065-81-8P 206065-83-0P  
 206065-84-1P 206065-85-2P 206065-86-3P  
 206065-96-5P 206065-97-6P 206065-98-7P  
 206066-00-4P 206066-02-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of indole derivs. as hypoglycemics and phosphodiesterase 5 inhibitors)

RN 206065-16-9 CAPLUS  
 CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-31-8 CAPLUS  
 CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-methoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-53-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-55-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-nitrophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-57-8 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-59-0 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(3-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-61-4 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(2-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-63-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-fluorophenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-64-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-65-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(1-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-66-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-67-0 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(2,6-dimethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-68-1 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-bromophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-70-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-71-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-phenylazo)phenyl]sulfonyl- (9CI) (CA INDEX NAME)




RN 206065-72-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[4-(trifluoromethyl)phenyl]sulfonyl- (9CI) (CA INDEX NAME)



RN 206065-74-9 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(3,4-dimethoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-76-1 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-(1,1-

dimethylethyl)phenyl]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-77-2 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[ (3-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-81-8 CAPLUS

CN 1H-Indole-5-carboxamide, N-([1,1'-biphenyl]-4-ylsulfonyl)-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-83-0 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-84-1 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[(4-ethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-85-2 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-butylphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-86-3 CAPLUS


CN 1H-Indole-5-carboxamide, N-[(4-butoxyphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-96-5 CAPLUS  
 CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-97-6 CAPLUS  
 CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-98-7 CAPLUS  
 CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206066-00-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[ (3-chloro[1,1'-biphenyl]-4-yl)methyl] -N- [(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206066-02-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[ (3-chloro[1,1'-biphenyl]-4-yl)methyl] -2-methyl-N- [(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

53

THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT